Study design and participants
CLL
This phase 3, randomized, open-label, parallel-group registrational study was conducted at 196 sites in 21 countries (Supplementary Table Patients were considered eligible for the study if they were 18 years or older, had previously untreated active CLL requiring treatment as per iwCLL criteria